BioXcel Therapeutics, Inc.
BTAI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | 0.01 | -0.01 |
| FCF Yield | -88.58% | -122.72% | -81.49% | -63.18% |
| EV / EBITDA | -6.65 | -12.36 | -13.52 | -9.24 |
| Quality | ||||
| ROIC | -408.03% | -69.39% | -63.67% | -64.52% |
| Gross Margin | -51.67% | 100.00% | -127.32% | -446.73% |
| Cash Conversion Ratio | 0.61 | 0.66 | 1.66 | 1.36 |
| Growth | ||||
| Revenue 3-Year CAGR | -15.40% | -5.79% | 47.17% | 82.14% |
| Free Cash Flow Growth | -4.42% | 18.68% | 9.36% | 29.50% |
| Safety | ||||
| Net Debt / EBITDA | -5.76 | -10.93 | -10.83 | -6.60 |
| Interest Coverage | -3.75 | -3.30 | -2.60 | -4.04 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 0.02 | 1.23 | 0.77 |
| Cash Conversion Cycle | -7,991.32 | -95,194.29 | -1,624.02 | -1,026.74 |